These antibodies can modulate immune responses, inhibit cell signaling pathways, and neutralize pathogenic targets, making them valuable tools in precision medicine and targeted therapy.[7] Adalimumab, a monoclonal antibody targeting tumor necrosis factor alpha (TNF‐α), has demonstrated remarkable efficacy in the management of autoimmune disorders such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. The gene discussed is TNF; the disease is psoriasis.